More from the Company Monthly Newsletter September 2019

During the month of September, we have continued our development and documentation work. The negotiations regarding the long-term financing have continued. We presented QuickCool to members of the Swedish Shareholders' Association in Trollhättan.

The negotiations relating to the financing proposal are ongoing, with the goal of signing a letter of intent in October. As previously disclosed by QuickCool, the financing proposal comprises a potential “reverse merger” with a third party company with different activities in the nutritional supplements, biotech and pharma industries, of different nature from QuickCool’s business, through an acquisition of such company by QuickCool with the payment of the purchase price being made through the issuance of new QuickCool shares. Through this transaction a group would be established that could contribute to the long-term financing of QuickCool’s development project.

Once definitive terms have been agreed between the parties, the Board of Directors would make an announcement regarding the potential transaction (which currently is subject to a confidentiality agreement as per market practice) and call for an EGM for approval.

We presented QuickCool and our unique cooling solution to members of the Swedish Shareholders' Association in Trollhättan. Always rewarding to meet with inquisitive investors who pose the right questions.

Follow us on LinkedIn. Additional information about QuickCool and our solution may be found on our homepage: http://www.quickcool.se/en/home.html

Kind regards,
Fredrik

Fredrik Radencrantz
CEO

QuickCool AB 
Ideon Science Park
Beta 6, Scheelevägen 17 - SE-223 70 Lund - Sweden
E-mail: fredrik.radencrantz@quickcool.se Web: www.quickcool.se
Mobile +46 (0)73 834 1188

QuickCool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the QuickCool® SYSTEM. QuickCool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. QuickCool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se 

Tags:

Subscribe

Documents & Links